Dublin, Dec. 20, 2018 (GLOBE NEWSWIRE) -- The "Real World Evidence Solutions Market by Component, Therapeutic Area, End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The global real-world evidence market is projected to reach USD 1,348.1 million by 2023 from USD 689.9 million in 2018, at a CAGR of 14.3% during the forecast period.

The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), the shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs). However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection are restraining the growth of this market.

On the basis of the component, the real world evidence market is segmented into data sets and services. The services segment is expected to register the highest CAGR during the forecast period. The high growth rate of this segment is mainly due to the rising need to convert data into actionable evidence, growing need to reduce drug development delays, and availability of large amounts of healthcare data are the major factors driving market growth in this segment.

Based on end user, the real-world evidence (RWE) market is broadly segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users (academic institutions, patient advocacy groups, and health technology assessment agencies). The pharmaceutical & biopharmaceutical companies segment is the fastest-growing segment in the real world evidence market during the forecast period. The rising demand to assess comparative effectiveness of drugs in actual, real-world use and the value or economic impact from the use of new or existing drugs are the major factors driving the growth of the real world evidence market for pharmaceutical & medical device companies.

North America held the largest share of the global real-world evidence market in 2017. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, due to the increasing government initiatives for the adoption of RWE studies, the rising burden of chronic diseases, increasing demand for better healthcare services, and the rising geriatric population in the Asia Pacific region.

The prominent players in the global real-world evidence market are IQVIA (US), International Business Machines Corporation (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).

Key Topics Covered:
1 Real World Evidence Solutions Market: Introduction

2 Real World Evidence Solutions Market: Research Methodology

3 Real World Evidence Solutions Market: Executive Summary

4 Real World Evidence Solutions Market: Premium Insights
4.1 Real-World Evidence: Market Overview
4.2 Europe Real-World Evidence Market, By Therapeutic Area and Country
4.3 Market: Geographic Snapshot
4.4 Real-World Evidence: Geographic Mix

5 Real World Evidence Solutions Market: Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
5.2.1.2 Shift From Volume- to Value-Based Care
5.2.1.3 Delays in Drug Development and the Subsequent Increase in Development Costs
5.2.2 Restraints
5.2.2.1 Reluctance to Rely on Real-World Studies
5.2.3 Opportunities
5.2.3.1 Growth Opportunities in Emerging Markets
5.2.3.2 Rising Focus on End-To-End Rwe Services
5.2.4 Challenges
5.2.4.1 Lack of Universally Accepted Methodological Standards and Data Processing Infrastructure

6 Industry Trends
6.1 Industry Trends
6.1.1 Emerging Role of Wearable Devices
6.1.2 Social Media Sourced Real-World Evidence
6.1.3 Incorporation of Artificial Intelligence in Real-World Data Management
6.2 Real-World Data Sources

7 Real World Evidence Solutions Market: By Component
7.1 Introduction
7.2 Data Sets
7.2.1 Clinical Settings Data
7.2.2 Claims Data
7.2.3 Pharmacy Data
7.2.4 Patient-Powered Data
7.3 Services

8 Real World Evidence Solutions Market: By Therapeutic Area
8.1 Introduction
8.2 Oncology
8.3 Cardiovascular Disease
8.4 Neurology
8.5 Immunology
8.6 Other Therapeutic Areas

9 Real World Evidence Solutions Market: By End User
9.1 Introduction
9.2 Pharmaceutical & Medical Device Companies
9.3 Healthcare Payers
9.4 Healthcare Providers
9.5 Other End Users

10 Real World Evidence Solutions Market: By Region

11 Competitive Landscape
11.1 Overview
11.2 Competitive Scenario
11.2.1 Mergers & Acquisitions
11.2.2 Partnerships, Agreements, Alliances, and Collaborations
11.2.3 Services Launches

12 Company Profiles
12.1 Iqvia
12.2 IBM
12.3 Pharmaceutical Product Development
12.4 Parexel
12.5 Optum (A Subsidiary of United Health Group, Inc.)
12.6 Perkinelmer
12.7 Icon PLC
12.8 Oracle
12.9 Cognizant
12.10 Syneos Health
12.11 Anthem
12.12 Clinigen
12.13 SAS Institute

For more information about this report visit https://www.researchandmarkets.com/research/hjbm4q/1_34_bn_real?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Healthcare Services

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.